Oncology
The Role of the Pharmacist in Hematologic Malignancies
The incidence of hematologic malignancies (leukemias, lymphomas and myelomas) in the Kingdom of Saudi Arabia (KSA) is on the rise. For example, according to the Saudi Cancer Registry, leukemia was the 5th most common cancer diagnosed in both genders between the years of 1999-2013. Hodgkin’s lymphoma accounts for 3.6% of all cancers in KSA and is the 7th most common cancer in Saudi males and the 8th most common cancer in Saudi females.
The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of leukemias, lymphomas, and myelomas, including current Saudi guidelines for selected malignancies.
DURATION
2 hr
PROFESSION
Pharmacy, Specialist
# OF CREDITS
1.0
ACCREDITATION
SCFHS
EXPIRY DATE
2024-07-26
The incidence of hematologic malignancies (leukemias, lymphomas and myelomas) in the Kingdom of Saudi Arabia (KSA) is on the rise. For example, according to the Saudi Cancer Registry, leukemia was the 5th most common cancer diagnosed in both genders between the years of 1999-2013. Hodgkin’s lymphoma accounts for 3.6% of all cancers in KSA and is the 7th most common cancer in Saudi males and the 8th most common cancer in Saudi females.
The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of leukemias, lymphomas, and myelomas, including current Saudi guidelines for selected malignancies.
This program is supported by Novartis.
Faculty
Dr. Riad al Fakih
Nora Alkhudair, reviewer
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Describe disease burden, risk factors, signs and symptoms and treatment for leukemias.
- Describe disease burden, risk factors, signs and symptoms and treatment for lymphomas.
- Describe disease burden, risk factors, signs and symptoms and treatment for myelomas.
- Explain the role of the pharmacist in promoting optimal patient outcomes in hematologic malignancies.
Accreditation
This program is accredited by the Saudi Commission for Health Specialties for 1.0 CPD Hour(s).
Activity Accreditation Number: ACA-20230002487.
Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.